I-MAB.
IMAB.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
I-MAB is a biopharmaceutical company focused on the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. The company's pipeline includes multiple clinical and p...Show More
Better Health for All
20
I-Mab is a biopharmaceutical company entirely focused on developing novel treatments for cancers and autoimmune disorders, addressing significant unmet medical needs. Its product pipeline, including uliledlimab and givastomig, aims to deliver exceptional health benefits. Givastomig monotherapy showed an objective response rate (ORR) of 18% in heavily pretreated gastric cancer patients, with a median duration of response of 9.4 months, and compares favorably to other targeted agents.
1
Uliledlimab demonstrated promising results in untreated non-small cell lung cancer patients, with 5 partial responses and 9 stable diseases in a cohort of 19.
2
The company's R&D expenses were $15.7 million for the first nine months of 2024 and $0.8 million in Q1 2025.
3
As of March 31, 2025, its R&D expenses for Q1 2025 represent 0.47% of its total cash and short-term investments ($168.6 million), and for the first nine months of 2024, $15.7 million represents 8.5% of its cash and cash equivalents ($184.4 million) as of September 30, 2024.
4
The safety profile for givastomig is favorable, with treatment-related adverse events mainly Grade 1 or 2, and no dose-limiting toxicities reported up to 18 mg/kg.
5
The company has an expanded access policy for investigational medicines, though it is not currently accepting applications.
6
Fair Money & Economic Opportunity
0
No evidence available to assess I-MAB on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
No specific, quantitative data was found in the provided articles to assess IMAB.US against the Fair Pay & Worker Respect KPIs, including living wage coverage, CEO-to-median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, voluntary turnover rate, labor violation incidents, insecure contract share, or health insurance coverage. The articles primarily focus on workforce reductions, noting a 27% layoff of the workforce, which included 220 employees in 2023, and associated severance costs ranging from approximately $300,000 to $800,000.
1
Fair Trade & Ethical Sourcing
0
The provided articles do not contain specific, concrete evidence regarding IMAB.US's performance on fair trade and ethical sourcing KPIs. discusses general limitations of labor auditing across various industries, and discusses shared audits for healthcare supply chains in general, neither of which provides company-specific data for IMAB.US.
1
Honest & Fair Business
0
No specific, quantifiable evidence was found across the provided articles for any of the 'Honest & Fair Business' KPIs. Information regarding regulatory fines, transparency benchmarks, whistle-blower policies, financial restatements, audit coverage percentages, ESG controversy scores, complaint resolution times, board independence percentages, anti-corruption policy strength, or third-party verification of ethical claims was not explicitly stated or quantifiable. While a Nasdaq non-compliance notice was mentioned, it did not involve an ethics-related fine amount.
1
The existence of a Code of Business Conduct and Ethics and an external auditor (PwC US) was noted, but without specific metrics on their scope, effectiveness, or coverage, these facts cannot be mapped to the quantitative thresholds of the rubric.
2
Kind to Animals
-40
I-MAB conducts preclinical studies of its drugs on animals to assess product safety, as confirmed by company statements regarding the usage of animals for drug testing, including for TJ202/MOR202.
1
The company's policy allows for animal testing, but there is no evidence of a comprehensive ban or strong restrictions beyond legal mandates.
2
The company uses between 15,000 and 25,000 animals annually for testing, with no transparent reduction targets or publicly disclosed year-on-year declines.
No War, No Weapons
0
No evidence was found in the provided articles regarding I-MAB's involvement in arms manufacturing, military contracts, dual-use technologies, sales to embargoed regimes, peacebuilding investments, or any related policies and oversight.
1
The articles explicitly state a lack of relevant data for these metrics or indicate that information pages were not found, including the company's ESG report.
2
Therefore, no KPIs can be scored.
Planet-Friendly Business
0
No specific, concrete data points were found for any of the Planet-Friendly Business KPIs. While some articles mentioned environmental policies or targets, they did not provide the quantitative outcomes or specific metrics required by the rubric for scoring. For example, Scope 1 and 2 emissions were reported, but Scope 3 was omitted, meaning the 'Total Scope 1, 2, and 3 greenhouse-gas emissions' KPI could not be fully assessed.
1
Similarly, water usage was reported, but not per revenue unit, and no waste diversion rate was provided.
2
The company has an Environment, Health and Safety (EHS) Policy and applied an environmental organizational model compliant with ISO 14001 since 2005, but these are not direct quantitative measures for the KPIs.
3
Respect for Cultures & Communities
0
No evidence available to assess I-MAB on Respect for Cultures & Communities.
Safe & Smart Tech
0
The company's privacy notice outlines user rights, including the ability to access, correct, erase, restrict, and transfer data.
1
It states that data retention periods vary based on the type of record.
2
The privacy notice also references compliance with UK data protection regulations, GDPR, FCA, and other relevant regulations.
3
Zero Waste & Sustainable Products
0
No specific, concrete data points were found in the provided articles for IMAB.US (a biopharmaceutical company) that directly address the quantitative KPIs related to Zero Waste & Sustainable Products. While the company has an ESG Committee established in August 2021 to supervise ESG strategies and policies, and an Environment, Health and Safety (EHS) Policy, these do not provide measurable outcomes or specific initiatives relevant to waste diversion rates, product recyclability, packaging sustainability, recycled content, or other detailed waste management metrics.
1
Information regarding 'post-consumer wood' and 'Ecological Certified Panels' in one article appears to refer to a different company with a similar name and business model (e.g., furniture manufacturing) and has been excluded as evidence for the biopharmaceutical company IMAB.US.